Modulation of hepcidin as therapy for primary and secondary iron overload disorders: Preclinical models and approaches

Hematology/Oncology Clinics of North America

Volumn 28, Issue 2, 2014, Pages 387-401

  Schmidt, Paul J ^a   Fleming, Mark D ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Thalassemia; Hepcidin minihepcidins; Hereditary hemochromatosis; Ineffective erythropoiesis; Iron metabolism; Lipid nanoparticle siRNA antisense oligonucleotide

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; FERROPORTIN; HEPCIDIN; IRON; SERINE PROTEINASE; TMPRSS6 PROTEIN; TRANSFERRIN; UNCLASSIFIED DRUG; GENISTEIN;

BETA THALASSEMIA; BETA THALASSEMIA INTERMEDIA; DRUG INHIBITION; GENE OVEREXPRESSION; GENETICS; HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; HUMAN; IRON METABOLISM; IRON OVERLOAD; LIVER CELL; MODULATION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; THALASSEMIA; THALASSEMIA INTERMEDIA; TRANSGENIC ANIMAL; ANIMAL; BETA-THALASSEMIA; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; METABOLISM;

ANIMALS; BETA-THALASSEMIA; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENISTEIN; HEPCIDINS; HUMANS; IRON; IRON OVERLOAD; TRANSFERRIN;

EID: 84896734636     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.11.004     Document Type: Review

References (73)

1. Krause A., Neitz S., Magert H.J., et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000, 480(2-3):147-150.
2. Pigeon C., Ilyin G., Courselaud B., et al. Anew mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. JBiol Chem 2001, 276(11):7811-7819.
3. Park C.H., Valore E.V., Waring A.J., et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. JBiol Chem 2001, 276(11):7806-7810.
4. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306(5704):2090-2093.
5. Finch C. Regulators of iron balance in humans. Blood 1994, 84(6):1697-1702.
6. Nicolas G., Chauvet C., Viatte L., et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. JClin Invest 2002, 110(7):1037-1044.
7. Adamsky K., Weizer O., Amariglio N., et al. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol 2004, 124(1):123-124.
8. Nemeth E., Roetto A., Garozzo G., et al. Hepcidin is decreased in TFR2 hemochromatosis. Blood 2005, 105(4):1803-1806.
9. Papanikolaou G., Samuels M.E., Ludwig E.H., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004, 36(1):77-82.
10. Bridle K.R., Frazer D.M., Wilkins S.J., et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003, 361(9358):669-673.
11. Schmidt P. Molecular basis of hemochromatosis. Metals in cells 2013, 361-372. John Wiley & Sons, Ltd, Chichester (United Kingdom). V.C. Culotta, R.S. Scott (Eds.).
12. Corradini E., Babitt J.L., Lin H.Y. The RGM/DRAGON family of BMP co-receptors. Cytokine Growth Factor Rev 2009, 20(5-6):389-398.
13. Babitt J.L., Lin H.Y. The molecular pathogenesis of hereditary hemochromatosis. Semin Liver Dis 2011, 31(3):280-292.
14. Babitt J.L., Huang F.W., Wrighting D.M., et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006, 38(5):531-539.
15. Yu P.B., Hong C.C., Sachidanandan C., et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008, 4(1):33-41.
16. Steinbicker A.U., Bartnikas T.B., Lohmeyer L.K., et al. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood 2011, 118(15):4224-4230.
17. Andriopoulos B., Corradini E., Xia Y., et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009, 41(4):482-487.
18. Meynard D., Kautz L., Darnaud V., et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009, 41(4):478-481.
19. Feder J.N., Gnirke A., Thomas W., et al. Anovel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13(4):399-408.
20. Feder J.N., Penny D.M., Irrinki A., et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998, 95(4):1472-1477.
21. West A.P., Giannetti A.M., Herr A.B., et al. Mutational analysis of the transferrin receptor reveals overlapping HFE and transferrin binding sites. JMol Biol 2001, 313(2):385-397.
22. Kawabata H., Yang R., Hirama T., et al. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. JBiol Chem 1999, 274(30):20826-20832.
23. Camaschella C., Roetto A., Cali A., et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000, 25(1):14-15.
24. Goswami T., Andrews N.C. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. JBiol Chem 2006, 281(39):28494-28498.
25. Gao J., Chen J., Kramer M., et al. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 2009, 9(3):217-227.
26. Schmidt P.J., Fleming M.D. Transgenic HFE-dependent induction of hepcidin in mice does not require transferrin receptor-2. Am J Hematol 2012, 87(6):588-595.
27. D'Alessio F., Hentze M.W., Muckenthaler M.U. The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation. JHepatol 2012, 57(5):1052-1060.
28. Du X., She E., Gelbart T., et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008, 320(5879):1088-1092.
29. Finberg K.E., Heeney M.M., Campagna D.R., et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008, 40(5):569-571.
30. Folgueras A.R., de Lara F.M., Pendas A.M., et al. Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood 2008, 112(6):2539-2545.
31. Melis M.A., Cau M., Congiu R., et al. Amutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica 2008, 93(10):1473-1479.
32. Silvestri L., Pagani A., Nai A., et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008, 8(6):502-511.
33. Maxson J.E., Chen J., Enns C.A., et al. Matriptase-2- and proprotein convertase-cleaved forms of hemojuvelin have different roles in the down-regulation of hepcidin expression. JBiol Chem 2010, 285(50):39021-39028.
34. Meynard D., Vaja V., Sun C.C., et al. Regulation of TMPRSS6 by BMP6 and iron in human cells and mice. Blood 2011, 118(3):747-756.
35. Maurer E., Gutschow M., Stirnberg M. Matriptase-2 (TMPRSS6) is directly up-regulated by hypoxia inducible factor-1: identification of a hypoxia-responsive element in the TMPRSS6 promoter region. Biol Chem 2012, 393(6):535-540.
36. Nicolas G., Viatte L., Lou D.Q., et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003, 34(1):97-101.
37. Levy J.E., Montross L.K., Cohen D.E., et al. The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Blood 1999, 94(1):9-11.
38. Nicolas G., Bennoun M., Porteu A., et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002, 99(7):4596-4601.
39. Kautz L., Meynard D., Besson-Fournier C., et al. BMP/Smad signaling is not enhanced in Hfe-deficient mice despite increased Bmp6 expression. Blood 2009, 114(12):2515-2520.
40. Corradini E., Garuti C., Montosi G., et al. Bone morphogenetic protein signaling is impaired in an Hfe knockout mouse model of hemochromatosis. Gastroenterology 2009, 137(4):1489-1497.
41. Corradini E., Schmidt P.J., Meynard D., et al. BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology 2010, 139(5):1721-1729.
42. Finberg K.E., Whittlesey R.L., Fleming M.D., et al. Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood 2010, 115(18):3817-3826.
43. Finberg K.E., Whittlesey R.L., Andrews N.C. Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice. Blood 2011, 117(17):4590-4599.
44. Semple S.C., Akinc A., Chen J., et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010, 28(2):172-176.
45. Schmidt P.J., Toudjarska I., Sendamarai A.K., et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood 2013, 121(7):1200-1208.
46. Guo S., Casu C., Gardenghi S., et al. Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. JClin Invest 2013, 123(4):1531-1541.
47. Bennett C.F., Swayze E.E. RNA targeting therapeutics: molecular mechanisms ofantisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010, 50:259-293.
48. Preza G.C., Ruchala P., Pinon R., et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. JClin Invest 2011, 121(12):4880-4888.
49. Ramos E., Ruchala P., Goodnough J.B., et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood 2012, 120(18):3829-3836.
50. Zhen A.W., Nguyen N.H., Gibert Y., et al. The small molecule, genistein, increases hepcidin expression in human hepatocytes. Hepatology 2013, 58(4):1315-1325.
51. Skow L.C., Burkhart B.A., Johnson F.M., et al. Amouse model for beta-thalassemia. Cell 1983, 34(3):1043-1052.
52. Yang B., Kirby S., Lewis J., et al. Amouse model for beta 0-thalassemia. Proc Natl Acad Sci USA 1995, 92(25):11608-11612.
53. Ginzburg Y.Z., Rybicki A.C., Suzuka S.M., et al. Exogenous iron increases hemoglobin in beta-thalassemic mice. Exp Hematol 2009, 37(2):172-183.
54. Li H., Rybicki A.C., Suzuka S.M., et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med 2010, 16(2):177-182.
55. Gardenghi S., Ramos P., Marongiu M.F., et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. JClin Invest 2010, 120(12):4466-4477.
56. Roy C.N., Mak H.H., Akpan I., et al. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 2007, 109(9):4038-4044.
57. Nai A., Pagani A., Mandelli G., et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood 2012, 119(21):5021-5029.
58. Zhang D.L., Hughes R.M., Ollivierre-Wilson H., et al. Aferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression. Cell Metab 2009, 9(5):461-473.
59. Zhang D.L., Senecal T., Ghosh M.C., et al. Hepcidin regulates ferroportin expression and intracellular iron homeostasis of erythroblasts. Blood 2011, 118(10):2868-2877.
60. Bauer D.E., Orkin S.H. Update on fetal hemoglobin gene regulation in hemoglobinopathies. Curr Opin Pediatr 2011, 23(1):1-8.
61. Sankaran V.G. Targeted therapeutic strategies for fetal hemoglobin induction. Hematology Am Soc Hematol Educ Program 2011, 2011:459-465.
62. Winichagoon P., Fucharoen S., Weatherall D., et al. Concomitant inheritance of alpha-thalassemia in beta 0- thalassemia/Hb E disease. Am J Hematol 1985, 20(3):217-222.
63. Kihm A.J., Kong Y., Hong W., et al. An abundant erythroid protein that stabilizes free alpha-haemoglobin. Nature 2002, 417(6890):758-763.
64. Yu X., Kong Y., Dore L.C., et al. An erythroid chaperone that facilitates folding of alpha-globin subunits for hemoglobin synthesis. JClin Invest 2007, 117(7):1856-1865.
65. Nasimuzzaman M., Khandros E., Wang X., et al. Analysis of alpha hemoglobin stabilizing protein overexpression in murine beta-thalassemia. Am J Hematol 2010, 85(10):820-822.
66. Chen J.J., Throop M.S., Gehrke L., et al. Cloning of the cDNA of the heme-regulated eukaryotic initiation factor 2 alpha (eIF-2 alpha) kinase of rabbit reticulocytes: homology to yeast GCN2 protein kinase and human double-stranded-RNA-dependent eIF-2 alpha kinase. Proc Natl Acad Sci USA 1991, 88(17):7729-7733.
67. Chen J.J., Pal J.K., Petryshyn R., et al. Amino acid microsequencing of internal tryptic peptides of heme-regulated eukaryotic initiation factor 2 alpha subunit kinase: homology to protein kinases. Proc Natl Acad Sci USA 1991, 88(2):315-319.
68. Chen J.J., Crosby J.S., London I.M. Regulation of heme-regulated eIF-2 alpha kinase and its expression in erythroid cells. Biochimie 1994, 76(8):761-769.
69. Chen J.J. Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias. Blood 2007, 109(7):2693-2699.
70. Han A.P., Yu C., Lu L., et al. Heme-regulated eIF2alpha kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency. EMBO J 2001, 20(23):6909-6918.
71. Han A.P., Fleming M.D., Chen J.J. Heme-regulated eIF2alpha kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and beta-thalassemia. JClin Invest 2005, 115(6):1562-1570.
72. Origa R., Galanello R., Ganz T., et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007, 92(5):583-588.
73. Pasricha S.R., Frazer D.M., Bowden D.K., et al. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major: a longitudinal study. Blood 2013, 122(1):124-133.